Patient characteristics
| Patient . | Age, y . | Sex . | Diagnosis . | Stage . | Prior therapies . | Cytoreductive therapy before T-cell infusions . |
|---|---|---|---|---|---|---|
| A | 44 | F | FL | IV-B | R-CHOP | CVP |
| B | 70 | M | FL | II-A | CHOP, rituximab, 131I-tositumomab | CVP |
| C | 47 | M | FL | IV-B | ProMACE/MOPP, ASCT, fludarabine (10 cycles) | CVP |
| D | 60 | M | FL | IV-A | Rituximab | CVP |
| E | 63 | M | MCL | IV-A | R-HyperCVAD, GCD-R | None |
| F | 46 | M | FL | IV-A | R-CVP | FND |
| G | 43 | M | FL | IV-A | CHOP, IFN, CY + VP16, R-CY, CY + DEX, GCD-R, ASCT | None |
| H | 46 | M | FL | IV-B | R-CHOP, fenretinide | FND |
| I | 77 | M | FL | III-A | R-CVP, R-CHOP, GCD-R | 131I-tositumomab |
| Patient . | Age, y . | Sex . | Diagnosis . | Stage . | Prior therapies . | Cytoreductive therapy before T-cell infusions . |
|---|---|---|---|---|---|---|
| A | 44 | F | FL | IV-B | R-CHOP | CVP |
| B | 70 | M | FL | II-A | CHOP, rituximab, 131I-tositumomab | CVP |
| C | 47 | M | FL | IV-B | ProMACE/MOPP, ASCT, fludarabine (10 cycles) | CVP |
| D | 60 | M | FL | IV-A | Rituximab | CVP |
| E | 63 | M | MCL | IV-A | R-HyperCVAD, GCD-R | None |
| F | 46 | M | FL | IV-A | R-CVP | FND |
| G | 43 | M | FL | IV-A | CHOP, IFN, CY + VP16, R-CY, CY + DEX, GCD-R, ASCT | None |
| H | 46 | M | FL | IV-B | R-CHOP, fenretinide | FND |
| I | 77 | M | FL | III-A | R-CVP, R-CHOP, GCD-R | 131I-tositumomab |
F indicates female; M, male; FL, follicular lymphoma; MCL, mantle cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, rituximab; CVP, cyclophosphamide, vincristine, and prednisone; ProMACE/MOPP, procarbazine, methotrexate with leucovorin, doxorubicin, cyclophosphamide, etoposide, mechlorethamine, vincristine, and prednisone; ASCT, high-dose therapy followed by autologous stem cell transplantation; HyperCVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with cycles of high-dose cytarabine and methotrexate; GCD, gemcitabine, carboplatin, and dexamethasone; FND, fludarabine, mitoxantrone, and dexamethasone; IFN, interferon-α; CY, cyclophosphamide; VP16, etoposide; and DEX, dexamethasone.